KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Moderna (MRNA) over the last 10 years, with Q3 2025 value amounting to $320.0 million.

  • Moderna's Current Deferred Revenue fell 3248.95% to $320.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $320.0 million, marking a year-over-year decrease of 3248.95%. This contributed to the annual value of $211.0 million for FY2024, which is 6758.83% down from last year.
  • Moderna's Current Deferred Revenue amounted to $320.0 million in Q3 2025, which was down 3248.95% from $283.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Current Deferred Revenue registered a high of $8.5 billion during Q3 2021, and its lowest value of $183.0 million during Q1 2025.
  • For the 5-year period, Moderna's Current Deferred Revenue averaged around $3.0 billion, with its median value being $1.7 billion (2023).
  • As far as peak fluctuations go, Moderna's Current Deferred Revenue skyrocketed by 374345.04% in 2021, and later tumbled by 7598.67% in 2023.
  • Over the past 5 years, Moderna's Current Deferred Revenue (Quarter) stood at $6.9 billion in 2021, then tumbled by 60.53% to $2.7 billion in 2022, then plummeted by 75.99% to $651.0 million in 2023, then crashed by 67.59% to $211.0 million in 2024, then soared by 51.66% to $320.0 million in 2025.
  • Its Current Deferred Revenue was $320.0 million in Q3 2025, compared to $283.0 million in Q2 2025 and $183.0 million in Q1 2025.